Pacira BioSciences (PCRX) Cost of Revenue (2010 - 2026)

Pacira BioSciences' Cost of Revenue history runs 17 years deep, the most recent figure standing at $36.4 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 6.14% year-over-year to $36.4 million; the TTM figure through Mar 2026 stood at $151.9 million (down 3.47% YoY), while the FY2025 annual figure was $149.7 million, down 12.13% from the prior year.
• Cost of Revenue was $36.4 million for Q1 2026 at Pacira BioSciences, down from $40.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $61.9 million in Q4 2022 to a low of $34.3 million in Q3 2025.
• Historically, Cost of Revenue has averaged $43.6 million across 5 years, with a median of $40.9 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue soared 58.73% in 2022, then slipped 27.65% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $61.9 million in 2022, then slipped by 22.97% to $47.7 million in 2023, then fell by 16.37% to $39.9 million in 2024, then climbed by 1.04% to $40.3 million in 2025, then declined by 9.64% to $36.4 million in 2026.
• The last three Cost of Revenue figures came in at $36.4 million (Q1 2026), $40.3 million (Q4 2025), and $34.3 million (Q3 2025), per Business Quant data.